Lord, Abbett & Co
WST icon

Lord, Abbett & Co’s West Pharmaceutical WST Stock Holding History

Lord, Abbett & Co’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-118,276
Closed -$38.7M – 590
2024
Q4 		$38.7M Buy
118,276
+17,985
+18% +$5.66M 0.12% 211
2024
Q3 		$30.1M Buy
100,291
+615
+0.6% +$188K 0.1% 254
2024
Q2 		$32.8M Sell
99,676
-1,504
-1% -$532K 0.11% 233
2024
Q1 		$40M Sell
101,180
-19,416
-16% -$7.18M 0.13% 213
2023
Q4 		$42.5M Sell
120,596
-20,838
-15% -$7.37M 0.15% 189
2023
Q3 		$53.1M Buy
141,434
+5,528
+4% +$2.14M 0.2% 149
2023
Q2 		$52M Buy
135,906
+53,507
+65% +$19.1M 0.18% 176
2023
Q1 		$28.5M Sell
82,399
-43,489
-35% -$12.7M 0.1% 287
2022
Q4 		$29.6M Sell
125,888
-39,585
-24% -$9.38M 0.11% 270
2022
Q3 		$40.7M Sell
165,473
-29,020
-15% -$8.84M 0.15% 185
2022
Q2 		$58.8M Buy
194,493
+5,779
+3% +$1.88M 0.21% 134
2022
Q1 		$77.5M Sell
188,714
-494
-0.3% -$193K 0.21% 142
2021
Q4 		$88.7M Buy
189,208
+50,654
+37% +$21.8M 0.2% 160
2021
Q3 		$58.8M Sell
138,554
-8,536
-6% -$3.6M 0.14% 221
2021
Q2 		$52.8M Sell
147,090
-12,221
-8% -$4.04M 0.13% 244
2021
Q1 		$44.9M Sell
159,311
-8,627
-5% -$2.47M 0.11% 285
2020
Q4 		$47.6M Sell
167,938
-46,907
-22% -$13.2M 0.13% 255
2020
Q3 		$59.1M Sell
214,845
-33,016
-13% -$8.74M 0.19% 166
2020
Q2 		$56.3M Buy
247,861
+181,903
+276% +$35.7M 0.2% 157
2020
Q1 		$10M Buy
+65,958
New +$10.2M 0.04% 435
2019
Q3 		– Sell
-51,500
Closed -$6.45M – 789
2019
Q2 		$6.45M Sell
51,500
-46,400
-47% -$5.48M 0.02% 631
2019
Q1 		$10.8M Sell
97,900
-34,600
-26% -$3.6M 0.04% 546
2018
Q4 		$13M Buy
+132,500
New +$14.4M 0.05% 487
2018
Q3 		– Sell
-101,855
Closed -$10.1M – 888
2018
Q2 		$10.1M Sell
101,855
-486,188
-83% -$44.8M 0.03% 620
2018
Q1 		$51.9M Sell
588,043
-363,296
-38% -$34M 0.15% 201
2017
Q4 		$93.9M Buy
951,339
+151,555
+19% +$14.9M 0.27% 89
2017
Q3 		$77M Buy
799,784
+531,207
+198% +$48.1M 0.22% 125
2017
Q2 		$25.4M Buy
268,577
+4,627
+2% +$426K 0.08% 383
2017
Q1 		$21.5M Sell
263,950
-80,700
-23% -$6.75M 0.06% 432
2016
Q4 		$29.2M Buy
344,650
+1,700
+0.5% +$134K 0.09% 323
2016
Q3 		$25.6M Sell
342,950
-449,987
-57% -$35.7M 0.08% 387
2016
Q2 		$60.2M Buy
792,937
+281,096
+55% +$20.5M 0.19% 152
2016
Q1 		$35.5M Buy
511,841
+224,991
+78% +$13.5M 0.11% 279
2015
Q4 		$17.3M Hold
286,850
– – 0.05% 473
2015
Q3 		$15.5M Sell
286,850
-9,550
-3% -$557K 0.05% 490
2015
Q2 		$17.2M Sell
296,400
-3,400
-1% -$190K 0.05% 523
2015
Q1 		$18.1M Sell
299,800
-62,285
-17% -$3.32M 0.05% 510
2014
Q4 		$19.3M Sell
362,085
-37,815
-9% -$1.89M 0.05% 475
2014
Q3 		$17.9M Sell
399,900
-53,700
-12% -$2.28M 0.04% 518
2014
Q2 		$19.1M Sell
453,600
-78,400
-15% -$3.36M 0.04% 531
2014
Q1 		$23.4M Sell
532,000
-73,300
-12% -$3.45M 0.05% 468
2013
Q4 		$29.7M Sell
605,300
-247,600
-29% -$11.6M 0.07% 427
2013
Q3 		$35.1M Sell
852,900
-442,500
-34% -$16.9M 0.08% 369
2013
Q2 		$45.5M Buy
+1,295,400
New +$42.6M 0.11% 281

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Lord, Abbett & Co's WST Position: Q1 2025 in Review

Lord, Abbett & Co sold out of West Pharmaceutical (WST) in Q1 2025, closing a stake of 118,276 shares — an estimated $38.7M sold.

Lord, Abbett & Co first reported a position in WST in Q2 2013 and held it in 44 quarters. The position peaked at $93.9M in Q4 2017. 713 funds tracked by Wall St. Rank hold WST as of Q1 2025.

  • Lord, Abbett & Co reported no remaining West Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 118,276 West Pharmaceutical shares in Q1 2025, an estimated $38.7M.
  • Lord, Abbett & Co first reported a position in West Pharmaceutical in Q2 2013 and held it in 44 quarters.
  • Lord, Abbett & Co's West Pharmaceutical position peaked at $93.9M in Q4 2017.
  • 713 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2025.

Based on Lord, Abbett & Co's 13F filing for Q1 2025, filed 13 May 2025.